Narrative identity, rationality, and microdosing classic psychedelics

Classic psychedelics such as LSD and psilocybin alter perception, mood and cognition, and recent scientific interest has focused on their therapeutic potential for conditions including end-of-life distress and addiction. In popular discourse there has been renewed attention to microdosing—regular ingestion of sub‑perceptual amounts of these substances—with users attributing improvements in mood, creativity and productivity to the practice, yet clinical evidence for these claims remains limited. Prior qualitative work has described motives and methods of microdosers but has not applied a theoretical identity framework to explain how people make sense of the practice within their everyday lives. Webb and colleagues set out to explore how people who microdose construct narratives about their practice using the narrative identity framework. The study aimed to understand why participants began microdosing, how they organised procurement and dosing, and how they reconciled microdosing with conventional social roles. To do this the investigators relied on semi‑structured interviews with 30 people who had engaged in microdosing, analysing how participants drew on cultural stories and symbolic boundaries when describing their behaviour.

This was a qualitative interview study based on semi‑structured interviews with 30 people who had microdosed classic psychedelics. Recruitment occurred between June 2017 and January 2018 using criterion‑based sampling via social media: the lead investigator posted invitations in Facebook groups and an online microdosing forum. Eligibility required participants to be aged 18 or older and to have practised microdosing—defined here as following a regimented schedule of small doses for at least five weeks—either at the time of interview or within the previous year. Interviews were conducted by telephone or via Facebook calls, recorded with participant consent using a commercially available phone recording app, lasted 30–75 minutes, and participants were not compensated. The interview guide asked participants to narrate when, how and why they began microdosing and probed motives, dosing amounts, procurement methods, schedules, and strategies for maximising benefits. Institutional Review Board approval was obtained at the lead author’s institution. Transcription was performed by three trained undergraduate research assistants and identifying information was removed. Analysis was inductive, with narrative identity and symbolic boundaries used as sensitising concepts. The lead and second author independently coded all transcripts, reconciled differences through peer debriefing and iterative recoding until consensus was reached. The investigators did not analyse responses separately by gender because they observed similar themes across men and women. Sample characteristics reported in the text: ages 18–69 (median 31), 20 men and 10 women, 24 self‑identified as White, 1 Asian, 3 Hispanic and 2 Middle Eastern. Thirteen participants microdosed psilocybin mushrooms, eleven used LSD or the analogue 1P‑LSD, and six used both; average microdosing duration was about one year (range two months to five years). Twelve participants reported current recreational use of psychedelics, twelve reported past recreational use, and six had never used recreational doses.

Participants consistently constructed microdosing as a rational, instrumental practice compatible with conventional, middle‑class life. Across interviews three interrelated emphases emerged: (1) practicality in procurement and dosing, (2) framing microdosing within a broader orientation to health and wellness, and (3) perceived benefits such as mood improvement, enhanced productivity and greater sociability. On procurement, many participants described deliberate strategies intended to reduce legal and health risks. They avoided buying from strangers, relied on known contacts when available (only 12 had such contacts when they began), or grew psilocybin mushrooms for personal use after researching cultivation techniques online; those who grew reported doing so for consumption or to share with friends rather than for profit. Several reported ordering 1P‑LSD online and considered it safer or legally less risky than street purchases; some also bought reagent testing kits. These practices were presented as evidence of careful, safety‑minded behaviour rather than reckless or hedonistic drug use. Dosing practices were similarly described as regimented and experimental. Typical reports were 0.2–0.5 g of psilocybin or approximately one‑tenth of a standard LSD dose every three to four days, with individuals using internet resources, literature and trial‑and‑error to calibrate their dose. Some placed mushroom material into capsules to aid precise dosing and to make the practice appear medicinal. Participants stressed testing new doses on non‑work days to avoid unwanted perceptual effects and to refine a dose that supported productivity rather than distraction. Participants located microdosing within broader practices of ‘‘living smart’’: many emphasised organic or natural remedies, self‑experimentation, interest in nootropics and a preference for minimising reliance on prescription pharmaceuticals. They framed microdosing as consistent with health‑conscious, evidence‑informed decision‑making, often invoking scientific articles or personal research as justification for their choices. When asked about outcomes, respondents reported a range of self‑perceived benefits. Mood enhancement was most commonly cited, including reductions in depressive and anxious symptoms and relief from grief or persistent low mood. Several participants attributed cessation of problematic substance use (heroin, prescription opioids, alcohol, cigarettes) to their microdosing regimens, and others described relief from physical symptoms such as headaches or menstrual pain. In occupational and creative domains, many reported increased focus, energy, creativity and productivity—effects described as subtle but cumulative rather than dramatic. Increased sociability and reduced social anxiety were also frequent themes, with some describing microdosing as a preferred social lubricant compared with alcohol. Select participant quotations were used in the text to illustrate these claims. Overall, the results show that participants narrated their microdosing as a controlled, goal‑oriented practice that reinforced their identities as responsible, conventional citizens rather than as recreational or deviant drug users.

Webb and colleagues conclude that participants predominantly drawn from middle‑class, often White, professional or student backgrounds narrated microdosing in ways that emphasised middle‑class values—curiosity, self‑control, ambition and optimisation. By framing microdosing as a rational, health‑oriented strategy to become ‘‘better’’ workers and people, participants constructed symbolic boundaries that distanced themselves from stereotypical portrayals of recreational or problematic drug users. This narrative work normalised their drug use and, according to the authors, likely supports the persistence of the practice. The investigators note important limitations: the use of a non‑probability sample recruited from online microdosing forums likely shaped the sample’s demographic composition and the forms of narrative available to participants, so findings should not be generalised to all people who microdose. They also acknowledge that participants’ accounts of benefits are self‑reports not verified by clinical trials, though they point to emerging empirical assessments that tentatively support some cognitive and affective effects. Finally, the authors stress that the purpose of the study was to describe how microdosers make sense of their practice rather than to evaluate efficacy. They argue that applying a narrative identity framework illuminates how cultural stories and symbolic boundary work shape drug‑using practices and identities, and recommend further research on more diverse populations and on the relationship between narrative constructions and actual outcomes.